Trial Profile

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NNZ 2591 (Primary)
Indications Pitt-Hopkins syndrome
Focus Adverse reactions; Pharmacokinetics
Acronyms PTHS-001
Sponsors Neuren Pharmaceuticals

Most Recent Events

22 Jan 2025 According to a Neuren Pharmaceuticals media release, company will present data at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, being held on 18-22 March 2025, in Los Angeles.
08 Aug 2024 Status changed from active, no longer recruiting to completed.
27 May 2024 Results published in the Neuren Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com